Naldemedine

Naldemedine
Clinical data
Trade namesSymproic, Rizmoic
Other namesS-297,995
AHFS/Drugs.comMonograph
MedlinePlusa617031
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding93–94%
Metabolismprimarily CYP3A4
Elimination half-life11 hrs
ExcretionUrine, feces
Identifiers
  • 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC32H34N4O6
Molar mass570.646 g·mol−1
3D model (JSmol)
  • CC(C)(c1nc(no1)c2ccccc2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)Cc7c6c(c(cc7)O)O4)CC8CC8)O
  • InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1
  • Key:AXQACEQYCPKDMV-RZAWKFBISA-N

Naldemedine, sold under the brand name Symproic in the US and Rizmoic in the European Union, is a medication that is used for the treatment of opioid-induced constipation in adults who have previously been treated with a laxative in the European Union, or to treat opioid induced constipation in adults with chronic non-cancer pain in the US. It is a peripherally acting μ-opioid receptor antagonist and was developed by Shionogi.[3] Clinical studies have found it to possess statistically significant effectiveness for these indications and to be generally well tolerated, with predominantly mild to moderate gastrointestinal side effects.[4] Effects indicative of central opioid withdrawal or impact on the analgesic or miotic effects of co-administered opioids have only been observed in a small number of patients.[1]

Medical uses

In the US, naldemedine is approved for the treatment of opioid induced constipation in adults with chronic non-cancer pain, including those who have chronic pain related to prior cancer or its treatment and do not need frequent opioid dosage escalation.[1]

In the European Union, naldemedine is also approved for the treatment of opioid induced constipation in adults, but as a second-line therapy after treatment with a laxative.[5]

Contraindications

The drug is contraindicated in patients with gastrointestinal obstruction or perforation, or those at risk for these problems.[1][5]

Side effects

Side effects in studies were abdominal pain (8–11% of patients as compared to 2–5% under placebo, depending on the study), diarrhea (7% versus 2–3%), nausea (4–6% versus 2–5%), vomiting (3% versus 2%), gastroenteritis (2–3% versus 1%), and opioid withdrawal syndrome (1.5–3.2% versus 0.5–1.5%). The latter was severe but manageable in one patient, and otherwise mild to moderate. Hypersensitivity reactions were rare; they occurred in two patients.[1][5]

Overdose

Single doses up to 500 times the recommended dose, as well as multiple doses up to 150 times the recommended dose for ten days, resulted in an increase of the mentioned side effects. Theses side effects were mild to moderate.[1][5]

Interactions

As naldemedine is mainly metabolized by the liver enzyme CYP3A4, inhibitors of this enzyme can increase its concentrations in the body and thus its potential for side effects. Examples include itraconazole (which increased naldemedine exposure 2.9-fold in a study), ketoconazole, clarithromycin and grapefruit juice. Conversely, CYP3A4 inducers such as rifampicin and St John's wort decrease naldemedine concentrations; with rifampicin, the reduction was 83% in a study.[1][5]

Strong inhibitors of the pump P-glycoprotein such as ciclosporin may increase naldemedine concentrations in the blood plasma.[1][5]

Pharmacology

Mechanism of action

Further information: Peripherally acting μ-opioid receptor antagonists § Mechanism of action

Naldemedine is a derivative of naltrexone and, like this substance, blocks opioid receptors of the types μ (mu), δ (delta) and κ (kappa). While naltrexone is able to cross the blood–brain barrier and can therefore be used to treat opioid dependence, the large hydrophilic side chain of naldemedine and its affinity to P-glycoprotein result in negligible concentrations in the central nervous system when recommended doses are applied. Instead, it acts mainly on μ-receptors in the gastrointestinal tract, where it counteracts the constipation inducing effects of opioid drugs.[5]

Pharmacokinetics

After oral intake, naldemedine has an absolute bioavailability in the range of 20% to 56% and reaches highest blood plasma levels after 0.75 hours when taken without food and 2.5 hours when taken with a high-fat meal. As the area under the curve is not significantly different with or without a meal, the drug can be taken independently of food. Once in the bloodstream, 93 to 94% of the substance is bound to plasma proteins, mainly to albumin.[1][5]

Naldemedine is mainly metabolized by the enzyme CYP3A4 to nor-naldemedine[6] (which makes up about 9–13% of the circulating substance), and to a much lesser extent by UGT1A3 to naldemedine 3-glucuronide. Minor metabolites are the 6-glucuronide, the 7-(R/S)-hydroxy-derivates, and two products formed by enterobacteria through cleaving the oxadiazole ring: naldemedine carboxylic acid and benzamidine. Nor-naldemedine, the glucuronides, and the carboxylic acid are opioid receptor antagonists, but less potent than the original substance.[7]

Naldemedine and its metabolites are excreted via urine and faeces. The part of the molecule "left" of the cleavage line (the sum of original substance, nor-naldemedine, glucuronides, hydroxy-derivative, and carboxylic acid) is found to 20.4% in the urine and to 64.3% in the faeces, while the part "right" to the line (the sum of original substance, nor-naldemedine, glucuronides, hydroxy-derivative, and benzamidine) is found to 57.3% in the urine and to 34.8% in the faeces. This indicates that benzamidine is predominantly excreted in the urine and the carboxylic acid is predominantly excreted in the faeces. The terminal half-life is about 11 hours.[5][7]

Chemistry

Naldemedine is used in form of the tosylate, a white to light tan powder. It is not hygroscopic and has a high water solubility at a physiologic pH.[7]

Society and culture

Commercialization

Naldemedine is manufactured by Shionogi Inc., a United States–based subsidiary of Shionogi & Co., Ltd. Shionogi & Co., Ltd. (SGIOF) is a pharmaceutical company founded in 1878 based in Osaka, Japan. Shionogi Inc. is fully funded by its parent company, Shionogi & Co., Ltd. The parent company specializes in pharmaceuticals, diagnostic reagents and medical devices in Japan and internationally. Naldemedine is their only gastroenterology product in the United States.

In the US market, Shionogi Inc. has partnered with Purdue Pharma in a joint venture for US commercialization of Symproic.[8] Purdue Pharma LP is a privately held pharmaceutical company based in the United States that specializes in chronic pain disorders.[9]

Purdue Pharma appealed to remove the Class II scheduling of Symproic as accordant to the Controlled Substances Act. The appeal was posted to the Federal Register on 12 July 2017.[10] The Drug Enforcement Administration officially removed the Class II scheduling in September 2017.[11]

Manufacturer finances

Since 2015, Shionogi & Co., Ltd. has produced increasing net income. At the end of fiscal year 2016, Shionogi & Co., Ltd. had a net income of $66,687,000. At the end of fiscal year 2017, they increased their net income to $83,879,000.[12] How much of this is attributed to sales of Symproic is unknown. Shionogi & Co., Ltd. ends their fiscal year on 31 March of each year. Considering the drug was only FDA approved on 23 March 2017, the true valuation of the drug is yet to be seen. Purdue Pharma has begun advertising for the medication to be available by October 2017.[13]

Intellectual property

There are three patents issued for naldemedine tosylate by the United States Patent and Trademark Office. All patents are owned by Shionogi Inc. and will expire from 2026 to 2031.[14] Naldemedine tosylate has 46 other patents in 18 different countries.[15]

Clinical trials

The approval of naldemedine came from the results of the COMPOSE program, a phase three clinical studies program conducted in adults 18–80 years of age with chronic non-cancer pain opioid induced constipation. COMPOSE-I and COMPOSE-II were 12-week double blind randomized controlled trials comparing the use of naldemedine to placebo in the patient population. COMPOSE-I began in August 2013 until January 2015 in 68 outpatient clinic in seven countries. COMPOSE-II began in November 2013 until June 2015 taking place in 69 outpatient clinics in six countries. In both trials, patients were randomly assigned to receive either naldemedine 0.2 mg or placebo once daily for 12 weeks. A responder had at least three spontaneous bowel movements per week with an increase of one spontaneous bowel movement for nine of the 12 weeks, including three of the final four weeks of the study. In COMPOSE-I and COMPOSE-II, the proportion of responders were significantly higher in the naldemedine group than the placebo group. Adverse events were similar in both trials, however, patients in the naldemedine group had slightly higher rates of adverse events.[16]

COMPOSE-III was a 52-week clinical trial examining the long term safety with naldemedine in patients with non cancer chronic pain. Results from this trial showed statistical significance for increased weekly bowel movements and no opioid withdrawal symptoms. The study also concluded adverse effects were more similar between two groups.[17]

References

  1. ^ a b c d e f g h i "Symproic- naldemedine tablet". DailyMed. 23 December 2022. Retrieved 13 June 2024.
  2. ^ "Rizmoic EPAR". European Medicines Agency. 18 February 2019. Retrieved 13 June 2024.
  3. ^ "Summary of product information from European Medicines Agency (EMA)" (PDF). EMA. 30 April 2024. Retrieved 30 April 2024.
  4. ^ Shionogi (27 March 2009). "Research and Development at Shionogi (as of March 2009)" (PDF). Archived from the original (PDF) on 22 May 2013. Retrieved 12 May 2012.
  5. ^ a b c d e f g h i "Rizmoic: EPAR – Product information" (PDF). European Medicines Agency (EMA). 29 August 2019.
  6. ^ Ohnishi S, Fukumura K, Kubota R, Wajima T (September 2019). "Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 49 (9): 1044–1053. doi:10.1080/00498254.2018.1536815. PMID 30351180. S2CID 53036507.
  7. ^ a b c "Rizmoic: EPAR – Public assessment report" (PDF). European Medicines Agency (EMA). 14 December 2018.
  8. ^ "Shionogi and Purdue Pharma establish alliance for joint U.S. commercialization of naldemedine". Purdue Pharma. Retrieved 31 October 2017.
  9. ^ "FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain". Purdue Pharma. Retrieved 31 October 2017.
  10. ^ "Schedules of controlled substances: removal of naldemedine from control" (PDF). Federal Register. Retrieved 1 November 2017.
  11. ^ "Symproic Now Available for Opioid-Induced Constipation". MPR. 12 October 2017. Retrieved 8 November 2017.
  12. ^ "Shionogi & Co., Ltd". Yahoo Finance. Retrieved 31 October 2017.
  13. ^ "Opioid Induced Constipation". Opioid Induced Constipation. Purdue Pharma. Retrieved 31 October 2017.
  14. ^ "Generic Symproic Availability". Drugs.com. Retrieved 31 October 2017.
  15. ^ "Naldemedine tosylate - generic drug details". Drug Patent Watch. Retrieved 31 October 2017.
  16. ^ Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC (August 2017). "Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials". The Lancet. Gastroenterology & Hepatology. 2 (8): 555–564. doi:10.1016/S2468-1253(17)30105-X. PMID 28576452.
  17. ^ "Center for Drug Evaluaiton and Research Medication Review" (PDF). FDA. Retrieved 31 October 2017.

Read other articles:

Apa Kabar (album)

Apa KabarAlbum studio karya U'CampDirilis24 April 2008Direkam2008GenreAlternative, Rock, Pop, Hip MetalDurasi?LabelNagaswaraProduserU'CampKronologi U'Camp Melangkah (album) (1998)String Module Error: Match not found1998 Apa kabar (2008) Apa Kabar merupakan album musik terkahir hasil karya U'Camp. Dirilis tahun 2008. Daftar lagu Apa Kabar Selingkungkuh Cinta Menanti Jawaban Gila Tapi Waras Preman Ku sudah Bosan Semesta Alam Relakan Izinkan Aku Bayangan lbsU'CampPersonilIram- (gitar) · Dhi...

 

 

Farah Maalim

Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Januari 2023. Farah Maalim Mohamed Wakil Ketua Majelis Nasional KenyaMasa jabatan15 Januari 2008 – 14 Januari 2013 PendahuluDavid MusilaPenggantiJoyce LabosoAnggota Parlemen dari Daerah Pilih LagderaMasa jabatan15 Januari 2008 – 14 Januari 2013...

 

 

Projection (alchemy)

In alchemy, using a Philosopher's Stone to transmute a lesser substance into a higher form This article is about the alchemical concept. For other uses, see Projection. Depiction of Sedziwój performing a transmutation for Sigismund III by Jan Matejko, 1867 Projection was the ultimate goal of Western alchemy. Once the philosopher's stone or powder of projection had been created, the process of projection would be used to transmute a lesser substance into a higher form; often lead into gold. T...

Arambourgiania

Genus of large azhdarchid pterosaur from the Late Cretaceous Not to be confused with Arambourgia. ArambourgianiaTemporal range: Maastrichtian PreꞒ Ꞓ O S D C P T J K Pg N Holotype fossil cast at Museum Histoire Naturelle, Paris Scientific classification Domain: Eukaryota Kingdom: Animalia Phylum: Chordata Order: †Pterosauria Suborder: †Pterodactyloidea Family: †Azhdarchidae Subfamily: †Quetzalcoatlinae Genus: †ArambourgianiaNessov vide Nessov & Yarkov, 1989 Species: †A....

 

 

Rekayasa Industri

PT Rekayasa IndustriNama dagangRekindJenisPerseroan terbatasIndustriKonstruksiDidirikan12 Agustus 1981; 42 tahun lalu (1981-08-12)KantorpusatJakarta, IndonesiaWilayah operasiIndonesiaTokohkunciTriyani Utaminingsih[1](Direktur Utama)Ngakan Timur Antara[1](Komisaris Utama)JasaEPCC dan pembangkitan listrikPendapatanRp 7,904 triliun (2019)[2]Laba bersihRp 217,992 milyar (2019)[2]Total asetRp 10,481 triliun (2019)[2]Total ekuitasRp 976,796 milyar (2019)...

 

 

Daftar duta besar Niger untuk Indonesia

Duta Besar Niger untuk IndonesiaPetahanaLeko Adosejak 2019 Berikut adalah daftar duta besar Republik Niger untuk Republik Indonesia. Nama Kredensial Selesai tugas Ref. Leko Ado 20 November 2019 Petahana [1][cat. 1] Catatan ^ Berkedudukan di New Delhi. Lihat pula Daftar Duta Besar Indonesia untuk Niger Daftar duta besar untuk Indonesia Referensi ^ Presiden Jokowi Terima Surat Kepercayaan 14 Duta Besar Negara Sahabat. Kementerian Sekretariat Negara Republik Indonesia. 20 No...

Labor relations

Study of work and workers Vancouver Labour Temple during the general strike in 1918 Labor relations or labor studies is a field of study that can have different meanings depending on the context in which it is used. In an international context, it is a subfield of labor history that studies the human relations with regard to work in its broadest sense and how this connects to questions of social inequality. It explicitly encompasses unregulated, historical, and non-Western forms of labor. Her...

 

 

Samsung E1107

Mobile phone model Samsung E1107ManufacturerSamsungCompatible networksGSM 900, GSM 1800SuccessorSamsung S7550Form factorcandybarDimensions105.2 x 44.15 x 16.4Mass119 gStorage1.5MB (up to 500 contacts)BatteryLi-ion 800 mAhDisplay128x128px, 1.52, 65K CSTNData inputsNumeric keypadOthersolar panel The Samsung E1107 (also known as Crest Solar or Solar Guru) is a mobile phone designed for a rural lower budget market. It was first released in India on July 10, 2009 with an initial price of ₹2,799....

 

 

Honorifics in Judaism

Terms of honor in Judaism This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Honorifics in Judaism – news · newspapers · books · scholar · JSTOR (August 2018) (Learn how and when to remove this message) There are a number of honorifics in Judaism that vary depending on the status of, and the relationship to, t...

Outville, Ohio

Unincorporated community in Ohio, U.S. The Outville Depot, a historic site Outville is an unincorporated community in Licking County, in the U.S. state of Ohio.[1] History Outville had its start when the railroad was extended to that point.[2] A post office was established at Outville in 1858, and remained in operation until 1960.[3] References ^ U.S. Geological Survey Geographic Names Information System: Outville, Ohio ^ Brister, Edwin M. P. (1909). Centennial History...

 

 

William Terrell

American politician For the Florida Supreme Court justice, see William Glenn Terrell. Official portrait, c.1850s William Terrell (1786 – July 4, 1855) was elected as a United States representative from Georgia.[1][2] Family See also: Terrell (surname) He was one of two children born to Joel and Lucy (Ragland) Terrell.[2][3] He was born in either Fairfax County[1] (or Louisa County),[2] Virginia. He moved with his parents to Wilkes County, Geor...

 

 

Dayr Hafir

Dayr HafirNom officiel (ar) دير حافرNom local (ar) دير حافرGéographiePays  SyrieGouvernorat AlepDistrict District de Dayr Hafir (chef-lieu)Sous-district Dayr Hafir Subdistrict (d)Superficie 5,7 km2Altitude 342 mCoordonnées 36° 09′ 33″ N, 37° 42′ 15″ EDémographiePopulation 35 409 hab. (2013)Densité 6 212,1 hab./km2 (2013)FonctionnementStatut Populated place in Syria (d) Géolocalisation sur la carte ...

Barlow Road

Historic road in Oregon Barlow RoadRoute of the Barlow Road (red); some consider the yellow route from The Dalles as part of the roadLocationOregon, USANearest cityThe DallesGovernment CampOregon CityEstablished1845Barlow RoadU.S. National Register of Historic PlacesU.S. Historic district NRHP reference No.92000334[1]Added to NRHPApril 13, 1992 The Barlow Road (at inception, Mount Hood Road) is a historic road in what is now the U.S. state of Oregon. It was built in 184...

 

 

1998 Indian general election

1998 Indian general election ← 1996 16, 22 and 28 February 1998 1999 → ← outgoing memberselected members →543 of the 545 seats in the Lok Sabha272 seats needed for a majorityRegistered605,880,192Turnout61.97% ( 4.03pp)   First party Second party Third party   Leader Atal Bihari Vajpayee Sitaram Kesri Harkishan Singh Surjeet Party BJP INC CPI(M) Alliance NDA INC+ LF Last election 20.29%, 161 seats 28.80%, 140 seats 6.12%, 32 seats Sea...

 

 

Presidenti della Repubblica Ceca

Presidente della Repubblica Ceca Prezident České republikyStendardo presidenziale della Repubblica Ceca Petr Pavel, attuale Presidente della Repubblica Ceca Stato Rep. Ceca TipoCapo di Stato In caricaPetr Pavel da9 marzo 2023 Istituito2 febbraio 1993 PredecessorePresidente della Cecoslovacchia Nominato davoto popolare Durata mandatocinque anni, rinnovabile una volta consecutivamente Bilancio2.235.600 Kč (86830 $)[1] SedeCastello di Praga, Praga Sito webwww.hrad.cz/ Modifi...

台湾海峡通道

本文或本章節是關於未來的公共运输建設或計划。未有可靠来源的臆測內容可能會被移除，現時內容可能與竣工情況有所出入。 此条目讲述中国大陆處於施工或详细规划阶段的工程。设计阶段的資訊，或許与竣工后情況有所出入。无可靠来源供查证的猜测会被移除。 设想中的三条路线方案[1]。 臺灣海峽隧道或臺湾海峡橋隧（英語：Taiwan Strait Tunnel Project）是一项工程�...

 

 

List of Spanish inventions and discoveries

The following list is composed of items, techniques and processes that were invented by or discovered by people from Spain. Spain was an important center of knowledge during the medieval era. While most of western and southern Europe suffered from the collapse of the Roman Empire, although declining, some regions of the former empire, Hispania (the Iberian Peninsula), southern Italy, and the remainder of the Eastern Roman Empire or Byzantine Empire, did not to suffer from the full impact of ...

 

 

Comunità Valenciana

Questa voce o sezione sull'argomento Spagna non cita le fonti necessarie o quelle presenti sono insufficienti. Puoi migliorare questa voce aggiungendo citazioni da fonti attendibili secondo le linee guida sull'uso delle fonti. Comunità Valencianacomunità autonomaComunitat ValencianaComunidad Valenciana (dettagli) Comunità Valenciana – VedutaIl Palau de la Generalitat Valenciana, sede della comunità autonoma LocalizzazioneStato Spagna AmministrazioneCapoluogo Valencia Presiden...

جيمس روبنسون (كاتب بريطاني)

  لمعانٍ أخرى، طالع جيمس روبنسون (توضيح). جيمس روبنسون (كاتب بريطاني)   معلومات شخصية الميلاد 1 أبريل 1963 (61 سنة)[1][2]  مانشستر  مواطنة المملكة المتحدة  الحياة العملية المواضيع قصص مصورة  المهنة فنان قصص مصورة،  وكاتب سيناريو،  ومخرج أفلام،  وكا�...

 

 

Сигизмунд III

В Википедии есть статьи о других людях с именем Сигизмунд. Сигизмунд IIIшвед. Sigismund III Якоб Трошель. Портрет короля Польши Сигизмунда III Вазы, 1610-е годы. Королевский замок в Варшаве Король польский и великий князь литовский 18 сентября 1587 — 19 апреля 1632 Девиз Pro jure et populo(За сп�...